Current Report Filing (8-k)
11 May 2016 - 8:12PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 10, 2016
Bio-Matrix
Scientific Group, Inc.
(Exact
Name of Company as Specified in Charter)
Commission File
Number: 0-32201
|
|
Delaware
|
33-0824714
|
(State or Other Jurisdiction of
Incorporation)
|
(IRS Employer Identification
Number)
|
4700
Spring Street, St 304
La
Mesa California, 91942
(Address
of Principal Executive Offices, Zip Code)
Company’s
telephone number, including area code:
(619) 702-1404
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On December 10, 2015 Regen Biopharma,
Inc. (“Regen”) was informed by the United States Food and Drug Administration that Regen has satisfactorily addressed
all clinical hold issues related to Regen’s Investigational New Drug Application for HemaXellerate and may initiate a Phase
I clinical trial assessing HemaXellerate in patients with drug-refractory aplastic anemia. The Phase I clinical trial is intended
to determine safety and potential efficacy of intravenously administered autologous stromal vascular fraction (SVF) cells in patients
with severe, immune suppressive refractory aplastic anemia with the primary endpoints of safety and feasibility and secondary endpoints
of efficacy as determined by patients having complete response, partial response or relapse.
The Company intends to amend its
Investigational New Drug Application for HemaXellerate in order that Regen may seek consent from the United States Food and Drug
Administration (FDA) to pursue both the previously described Phase I clinical trial assessing HemaXellerate in patients with drug-refractory
aplastic anemia and a Phase I clinical trial assessing HemaXellerate in patients suffering from chemotherapy-induced bone marrow
suppression.
HemaXellerate (a therapy under development
by Regen) is a patient-specific composition of cells that have been demonstrated to repair damaged bone marrow and stimulate production
of blood cells based on previous animal studies.
No assurance may be given that the
consent sought by Regen will be granted by the FDA or that the results of any clinical trial which may be conducted with regard
to any product or therapy under development by Regen will yield results favorable to Regen.
Regen is a controlled subsidiary
of Bio Matrix Scientific Group, Inc.
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
BIO MATRIX SCIENTIFIC GROUP, INC.
|
|
|
Dated: May 10, 2016
|
By:
/s/ David Koos
|
|
David Koos
|
|
Chief Executive Officer
|